Plain-English translation of NCT03801434 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can treat rare blood disorders where your body makes too many eosinophils (a type of white blood cell). The medication works by blocking certain proteins that may be causing your body to overproduce these cells. Researchers want to find out how well this treatment works and whether it's safe for patients like you.
People with these eosinophil disorders often need to take steroids, which can have serious side effects over time, or their disease doesn't respond well to current treatments. This trial aims to see whether this medication could offer a better option—one that might work without steroids or let patients take lower steroid doses.
You would take the medication by mouth twice daily for 28 days at a time, with treatment continuing for up to 6 cycles (about 6 months total) as long as the medication is helping and you're not experiencing serious side effects. During this time, you would have regular blood tests and check-ins with the research team to monitor how well the medication is working and to watch for any side effects. The trial is designed to track whether the treatment reduces your eosinophil counts, helps you feel better, and potentially allows you to reduce or stop steroid medications.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States